MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.440
+0.050
+3.60%
Closed 16:00 05/26 EDT
OPEN
1.380
PREV CLOSE
1.390
HIGH
1.460
LOW
1.380
VOLUME
54.95K
TURNOVER
49.48K
52 WEEK HIGH
3.990
52 WEEK LOW
1.020
MARKET CAP
41.15M
P/E (TTM)
-2.2447
1D
5D
1M
3M
1Y
5Y
Moleculin begins human trial of WP1122 to treat COVID-19
Moleculin Biotech (NASDAQ:MBRX +4.3%) said on Thursday it had begun dosing its first human in a Phase 1a study evaluating the safety and pharmacokinetics of its lead candidate, WP1122, to
Seekingalpha · 6h ago
Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122
Moleculin Biotech, Inc. (NASDAQ: MBRX) announced dosing of subjects in its Phase 1a clinical study of WP1122 in healthy volunteers for the treatment of COVID-19. The first-in-human Phase 1a study will evaluate the safety and pharmacokinetics (PK) of WP1122...
Benzinga · 8h ago
BRIEF-Moleculin Begins Dosing Healthy Volunteers In Phase 1a Clinical Trial Of COVID-19 Treatment
reuters.com · 10h ago
Moleculin Biotech Reports Began Dosing In Volunteers For Phase 1a Trial Of Co.'s WP1122 For Treatment Of COVID
– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to
Benzinga · 10h ago
Moleculin Biotech Starts Dosing For Phase 1a Study On Potential COVID-19 Treatment
MT Newswires · 12h ago
Moleculin to Present at the H.C. Wainwright Global Investment Conference
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief ...
PR Newswire · 05/19 12:05
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/17 11:30
30 Stocks Moving in Monday's Pre-Market Session
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.
Benzinga · 05/16 10:57
More
No Data
Learn about the latest financial forecast of MBRX. Analyze the recent business situations of Moleculin Biotec through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MBRX stock price target is 12.39 with a high estimate of 29.00 and a low estimate of 1.570.
High29.00
Average12.39
Low1.570
Current 1.440
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 43
Institutional Holdings: 3.23M
% Owned: 11.29%
Shares Outstanding: 28.58M
TypeInstitutionsShares
Increased
8
61.92K
New
3
15.19K
Decreased
3
17.31K
Sold Out
7
124.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of resistant cancers and viruses through the development of its drug candidates. The Company has three product pipelines: Annamycin, WP1066 and WP1122. Annamycin is developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). WP1066 is a immune or transcription modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG), which provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells.

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.